Lilly EXPEDITION data puts some flesh on solanezumab's bones
This article was originally published in Scrip
Executive Summary
The full data from Lilly's mixed EXPEDITION studies for its anti-amyloid Alzheimer's disease monoclonal antibody (MAb) candidate solanezumab have now been presented, bringing some clarity on the extent of the significant effects seen on some of the endpoint measures tested in the pivotal programme.